Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma: Where Are We Now and Which Way Should We Go?

Seminars in Hematology

Volumn 48, Issue 3, 2011, Pages 227-239

  Le Gouill, Steven ^a,b   Mohty, Mohamad ^a,b   Guillaume, Thierry ^a   Gastinne, Thomas ^a   Moreau, Philippe ^a,b  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b Team 12   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; SEROLIMUS; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

AGE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RELAPSE; DISEASE COURSE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LYMPHOMA EFFECT; HUMAN; MANTLE CELL LYMPHOMA; MORTALITY; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REFRACTORY PERIOD; TRANSPLANT RELATED MORTALITY; TREATMENT INDICATION; WHOLE BODY RADIATION;

DISEASE-FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, MANTLE-CELL; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 79960503895     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2011.03.009     Document Type: Article

References (75)

1. Andersen N.S., Jensen M.K., de Nully Brown P., Geisler C.H. A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors. Eur J Cancer 2002, 38:401-408.
2. Zhou Y., Wang H., Fang W., et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 2008, 113:791-798.
3. Zucca E., Roggero E., Pinotti G., et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995, 6:257-262.
4. Banks P.M., Chan J., Cleary M.L., et al. Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 1992, 16:637-640.
5. Raffeld M., Jaffe E.S. bcl-1, t(11;14), and mantle cell-derived lymphomas. Blood 1991, 78:259-263.
6. Williams M.E., Westermann C.D., Swerdlow S.H. Genotypic characterization of centrocytic lymphoma: frequent rearrangement of the chromosome 11 bcl-1 locus. Blood 1990, 76:1387-1391.
7. Perez-Galan P., Dreyling M., Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011, 11:26-38.
8. Jares P., Colomer D., Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007, 7:750-762.
9. Ghielmini M., Schmitz S.F., Cogliatti S., et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005, 23:705-711.
10. Herrmann A., Hoster E., Zwingers T., et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009, 27:511-518.
11. Dreyling M., Lenz G., Hoster E., et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005, 105:2677-2684.
12. Geisler C.H., Kolstad A., Laurell A., et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008, 112:2687-2693.
13. Lefrere F., Delmer A., Levy V., Delarue R., Varet B., Hermine O. Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. Haematologica 2004, 89:1275-1276.
14. Lefrere F., Delmer A., Suzan F., et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002, 16:587-593.
15. Milpied N., Gaillard F., Moreau P., et al. High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience. Bone Marrow Transplant 1998, 22:645-650.
16. Khouri I.F., Romaguera J., Kantarjian H., et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998, 16:3803-3809.
17. Tam C.S., Bassett R., Ledesma C., et al. Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009, 113:4144-4152.
18. Tam C.S., Khouri I.F. Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma. Leuk Lymphoma 2009, 50:1239-1248.
19. Schulz H., Bohlius J.F., Trelle S., et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007, 99:706-714.
20. Khouri I.F., Lee M.S., Romaguera J., et al. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol 1999, 10:1293-1299.
21. Williams M.E., Connors J.M., Dreyling M.H., et al. Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop. Leuk Lymphoma 2011, 52:24-33.
22. Ringden O., Karlsson H., Olsson R., Omazic B., Uhlin M. The allogeneic graft-versus-cancer effect. Br J Haematol 2009, 147:614-633.
23. Schmitz N., Dreger P., Glass B., Sureda A. Allogeneic transplantation in lymphoma: current status. Haematologica 2007, 92:1533-1548.
24. van Besien K., Loberiza F.R., Bajorunaite R., et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003, 102:3521-3529.
25. Khouri I.F. Reduced-intensity regimens in allogeneic stem-cell transplantation for non-hodgkin lymphoma and chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2006, 390-397.
26. Kroger N., Hoffknecht M., Kruger W., et al. Allogeneic bone marrow transplantation for refractory mantle cell lymphoma. Ann Hematol 2000, 79:578-580.
27. Sohn S.K., Baek J.H., Kim D.H., et al. Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed-DLIs for relapse after autologous transplantation in mantle cell lymphoma: a case report and literature review on the evidence of GVL effects in MCL. Am J Hematol 2000, 65:75-80.
28. Adkins D., Brown R., Goodnough L.T., Khoury H., Popovic W., DiPersio J. Treatment of resistant mantle cell lymphoma with allogeneic bone marrow transplantation. Bone Marrow Transplant 1998, 21:97-99.
29. Corradini P., Ladetto M., Astolfi M., et al. Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma. Br J Haematol 1996, 94:376-378.
30. Martinez C., Carreras E., Rovira M., et al. Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation. Bone Marrow Transplant 2000, 26:677-679.
31. Bloor A.J., Thomson K., Chowdhry N., et al. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008, 14:50-58.
32. Corradini P., Dodero A., Farina L., et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007, 21:2316-2323.
33. Khouri I.F., Lee M.S., Saliba R.M., et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003, 21:4407-4412.
34. Russell N.H., Byrne J.L., Faulkner R.D., Gilyead M., Das-Gupta E.P., Haynes A.P. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant 2005, 36:437-441.
35. Maris M.B., Sandmaier B.M., Storer B.E., et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004, 104:3535-3542.
36. Morris E., Thomson K., Craddock C., et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004, 104:3865-3871.
37. Perez-Simon J.A., Kottaridis P.D., Martino R., et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002, 100:3121-3127.
38. Cook G., Smith G.M., Kirkland K., et al. Outcome following reduced-intensity allogeneic stem cell transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2010, 16:1419-1427.
39. Armand P., Kim H.T., Ho V.T., et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008, 14:418-425.
40. Berdeja J.G., Jones R.J., Zahurak M.L., et al. Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma. Biol Blood Marrow Transplant 2001, 7:561-567.
41. Kasamon Y.L. Blood or marrow transplantation for mantle cell lymphoma. Curr Opin Oncol 2007, 19:128-135.
42. Kasamon Y.L., Jones R.J., Diehl L.F., et al. Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 2005, 11:39-46.
43. Ganti A.K., Bierman P.J., Lynch J.C., Bociek R.G., Vose J.M., Armitage J.O. Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol 2005, 16:618-624.
44. Laudi N., Arora M., Burns L., et al. Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma. Am J Hematol 2006, 81:519-524.
45. Rodriguez R., Nademanee A., Ruel N., et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006, 12:1326-1334.
46. Rifkind J., Mollee P., Messner H.A., Lipton J.H. Allogeneic stem cell transplantation for mantle cell lymphoma-does it deserve a better look?. Leuk Lymphoma 2005, 46:217-223.
47. Hamadani M., Benson D.M., Hofmeister C.C., et al. Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant 2009, 15:547-553.
48. Robinson SP, Taghipour G, Canals C, et al. Reduced-intensity conditioning and allogeneic stem cell transplantation in mantle cell lymphoma: update from the lymphoma working party of the EBMT. EBMT Meeting 2006. Hamburg, Germany; March 19-22, 2006.
49. Le Gouill S, Kröger N, Dhedin N, et al. Non-myeloablative allogeneic stem cell transplantation in mantle cell lymphoma. EBMT Meeting 2009. Goteborg, Sweden; March 29-April 1, 2009.
50. Robinson SP, Schmitz N, Taghipour T, Sureda A. Reduced intensity allogeneic stem cell transplantation for mantle cell lymphoma is associated with substantial late transplant relapted mortality and a poor outcome in patients with chemoresistant disease [abstract 2260]. EBMT Meeting 2004. Barcelona, Spain; March 28-31, 2004.
51. Robinson S.P., Goldstone A.H., Mackinnon S., et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002, 100:4310-4316.
52. Dreyling M., Beelen D.W., Schleuning M., et al. Allogeneic stem cell transplantation with dose-reduced conditioning in relapsed follicular and mantle cell lymphoma-a prospective phase II trial of the german low grade lymphoma study group [abstract]. Blood 2007, 110.
53. Gayoso J, Martino R, Balsalobre P, et al. Long-term results of fludarabine/melphalan as reduced-intensity conditioning regimen in mantle cell lymphoma: age matters. EBMT Meeting 2009. Goteborg, Sweden; March 29-April 1, 2009.
54. Mohty M., Marchetti N., El-Cheikh J., Faucher C., Furst S., Blaise D. Rituximab as salvage therapy for refractory chronic GVHD. Bone Marrow Transplant 2008, 41:909-911.
55. Ratanatharathorn V., Ayash L., Reynolds C., et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003, 9:505-511.
56. Lenz G., Hiddemann W., Dreyling M. The role of fludarabine in the treatment of follicular and mantle cell lymphoma. Cancer 2004, 101:883-893.
57. Forstpointner R., Dreyling M., Repp R., et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004, 104:3064-3071.
58. Bethge W.A., Lange T., Meisner C., et al. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study. Blood 2010, 116:1795-1802.
59. 90Y-ibritumomab-tiuxetan. Leuk Lymphoma 2006, 47:59-63.
60. Goy A., Younes A., McLaughlin P., et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:667-675.
61. O'Connor O.A., Wright J., Moskowitz C., et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005, 23:676-684.
62. Wiernik P.H., Lossos I.S., Tuscano J.M., et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:4952-4957.
63. Pott C., Schrader C., Gesk S., et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 2006, 107:2271-2278.
64. Andersen N.S., Pedersen L.B., Laurell A., et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol 2009, 27:4365-4370.
65. Ladetto M., Magni M., Pagliano G., et al. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. Biol Blood Marrow Transplant 2006, 12:1270-1276.
66. Bodet-Milin C., Touzeau C., Leux C., et al. Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. Eur J Nucl Med Mol Imaging 2010, 37:1633-1642.
67. Ek S., Dictor M., Jerkeman M., Jirstrom K., Borrebaeck C.A. Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood 2008, 111:800-805.
68. Katzenberger T., Petzoldt C., Holler S., et al. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 2006, 107:3407.
69. Rosenwald A., Wright G., Wiestner A., et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003, 3:185-197.
70. Brepoels L., Stroobants S., De Wever W., et al. Positron emission tomography in mantle cell lymphoma. Leuk Lymphoma 2008, 49:1693-1701.
71. Hoster E., Dreyling M., Klapper W., et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008, 111:558-565.
72. Salaverria I., Zettl A., Bea S., et al. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol 2007, 25:1216-1222.
73. Dreyling M., Weigert O., Hiddemann W. Current treatment standards and future strategies in mantle cell lymphoma. Ann Oncol 2008, 19(Suppl 4):41-44.
74. Gill S., Ritchie D. Therapeutic options in mantle cell lymphoma. Leuk Lymphoma 2008, 49:398-409.
75. Kiss T.L., Mollee P., Lazarus H.M., Lipton J.H. Stem cell transplantation for mantle cell lymphoma: if, when and how?. Bone Marrow Transplant 2005, 36:655-661.